Advanced Search
XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
Citation: XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
shu

Advances in research on tumor immunotherapy and its drug development

  • Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81872823) and the Double First-Class Project of China Pharmaceutical University (No.CPU2018PZQ13)
More Information
  • Received Date: June 24, 2020
  • Revised Date: July 09, 2020
    Graphical Abstract
    • Abstract
  • The progress of molecular biology and tumor biology has greatly changed the mode of cancer treatment. A large number of scientific studies have revealed the mechanism of tumor immune evasion, and a variety of new types of tumor immunotherapy have emerged, which has become another effective treatment of cancer after surgery, radiotherapy, chemotherapy and targeted therapy. This paper introduces the mechanism of tumor cell immune evasion, and focuses on the design principle, biological drugs and the latest research progress of immunotherapy, such as cytokine immunotherapies, therapeutic monoclonal antibody immunotherapy, PD-1/PD-L1 therapy, CAR-T therapy, tumor vaccine, oncolytic virus and so on. At the same time, the advantages and disadvantages of various immunotherapies are compared to provide reference for drug research and development in tumor immunotherapy.
    • FullText(HTML)
    • References (56)
  • [1]
    . Cell， 2019， 176（3）： 677.
    [2]
    Pham T， Roth S， Kong J， et al. An update on immunotherapy for solid tumors： a review［J］. Ann Surg Oncol， 2018， 25（11）： 3404-3412.
    [3]
    Chang CH， Qiu J， O''Sullivan D， et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression［J］. Cell， 2015， 162（6）： 1229-1241.
    [4]
    Klener P， Jr.， Otahal P， Lateckova L， et al. Immunotherapy approaches in cancer treatment［J］. Curr Pharm Biotechnol， 2015， 16（9）： 771-781.
    [5]
    Liu YH， Zang XY， Wang JC， et al. Diagnosis and management of immune related adverse events （irAEs） in cancer immunotherapy［J］. Biomedecine Pharmacother， 2019， 120： 109437.
    [6]
    Weiner GJ. Building better monoclonal antibody-based therapeutics［J］. Nat Rev Cancer， 2015， 15（6）： 361-370.
    [7]
    Sedykh SE， Prinz VV， Buneva VN， et al. Bispecific antibodies： design， therapy， perspectives［J］. Drug Des Devel Ther， 2018， 12： 195-208.
    [8]
    Labrijn AF， Janmaat ML， Reichert JM， et al. Bispecific antibodies： a mechanistic review of the pipeline［J］. Nat Rev Drug Discov， 2019， 18（8）： 585-608.
    [9]
    Lindau D， Gielen P， Kroesen M， et al. The immunosuppressive tumour network： myeloid-derived suppressor cells， regulatory T cells and natural killer T cells［J］. Immunology， 2013， 138（2）： 105-115.
    [10]
    Qin H， Lerman B， Sakamaki I， et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice［J］. Nat Med， 2014， 20（6）： 676-681.
    [11]
    Liu C， Workman CJ， Vignali DA. Targeting regulatory T cells in tumors［J］. Febs J， 2016， 283（14）： 2731-2748.
    [12]
    de Coa?a YP， Wolodarski M， Poschke I， et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma［J］. Oncotarget， 2017， 8（13）： 21539-21553.
    [13]
    Buchbinder EI， Desai A. CTLA-4 and PD-1 pathways： similarities， differences， and implications of their inhibition［J］. Am J Clin Oncol， 2016， 39（1）： 98-106.
    [14]
    Abdin SM， Zaher DM， Arafa EA， et al. Tackling cancer resistance by immunotherapy： updated clinical impact and safety of PD-1/PD-L1 inhibitors［J］. Cancers （Basel）， 2018， 10（2）： E32.
    [15]
    Iwai Y， Ishida M， Tanaka Y， et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade［J］. Proc Natl Acad Sci USA， 2002， 99（19）： 12293-12297.
    [16]
    Rowshanravan B， Halliday N， Sansom DM. CTLA-4： a moving target in immunotherapy［J］. Blood， 2018， 131（1）： 58-67.
    [17]
    Syn NL， Teng MWL， Mok TSK， et al. De-novo and acquired resistance to immune checkpoint targeting［J］. Lancet Oncol， 2017， 18（12）： e731-e741.
    [18]
    Dong HD， Strome SE， Salomao DR， et al. Tumor-associated B7-H1 promotes T-cell apoptosis： a potential mechanism of immune evasion［J］. Nat Med， 2002， 8（8）： 793-800.
    [19]
    Sul J，Blumenthal GM，Jiang XP， et al. FDA approval summary： pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1［J］. Oncologist， 2016， 21（5）： 643-650.
    [20]
    Ning YM， Suzman D， Maher VE， et al. FDA approval summary： atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy［J］. Oncologist， 2017， 22（6）： 743-749.
    [21]
    Michot JM， Bigenwald C， Champiat S， et al. Immune-related adverse events with immune checkpoint blockade： a comprehensive review［J］. Eur J Cancer， 2016， 54： 139-148.
    [22]
    Maude SL， Laetsch TW， Buechner J， et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia［J］. N Engl J Med， 2018， 378（5）： 439-448.
    [23]
    Locke FL， Ghobadi A， Jacobson CA， et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma （ZUMA-1）： a single-arm， multicentre， phase 1-2 trial［J］. Lancet Oncol， 2019， 20（1）： 31-42.
    [24]
    Frey N， Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy［J］. Biol Blood Marrow Transplant， 2019， 25（4）： e123-e127.
    [25]
    Neelapu SS， Locke FL， Bartlett NL， et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma［J］. N Engl J Med， 2017， 377（26）： 2531-2544.
    [26]
    Ji TJ， Lang JY， Ning B， et al. Enhanced natural killer cell immunotherapy by rationally assembling fc fragments of antibodies onto tumor membranes［J］. Adv Mater， 2019， 31（6）： e1804395.
    [27]
    Chiu J， Ernst DM， Keating A. Acquired natural killer cell dysfunction in the tumor microenvironment of classic Hodgkin lymphoma［J］. Front Immunol， 2018， 9： 267.
    [28]
    Ibrahim EC， Guerra N， Lacombe MJ， et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma［J］. Cancer Res， 2001， 61（18）： 6838-6845.
    [29]
    Hu Y， Tian ZG， Zhang C. Chimeric antigen receptor （CAR）-transduced natural killer cells in tumor immunotherapy［J］. Acta Pharmacol Sin， 2018， 39（2）： 167-176.
    [30]
    Han JF， Chu JH， Keung Chan W， et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells［J］. Sci Rep， 2015， 5： 11483.
    [31]
    Burger MC， Zhang C， Harter PN， et al. CAR-engineered NK cells for the treatment of glioblastoma： turning innate effectors into precision tools for cancer immunotherapy［J］. Front Immunol， 2019， 10： 2683.
    [32]
    Li Y， Hermanson DL， Moriarity BS， et al. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity［J］. Cell Stem Cell， 2018， 23（2）： 181-192.e5.
    [33]
    Liu E， Marin D， Banerjee P， et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors［J］. N Engl J Med， 2020， 382（6）： 545-553.
    [34]
    Hu Y， Tian ZG， Zhang C. Natural killer cell-based immunotherapy for cancer： advances and prospects［J］. Engineering， 2019， 5（1）： 106-114.
    [35]
    Song Q， Zhang CD， Wu XH. Therapeutic cancer vaccines： From initial findings to prospects［J］. Immunol Lett， 2018， 196： 11-21.
    [36]
    Bowen WS， Svrivastava AK， Batra L， et al. Current challenges for cancer vaccine adjuvant development［J］. Expert Rev Vaccines， 2018， 17（3）： 207-215.
    [37]
    van der Burg SH， Arens R， Ossendorp F， et al. Vaccines for established cancer： overcoming the challenges posed by immune evasion［J］. Nat Rev Cancer， 2016， 16（4）： 219-233.
    [38]
    Aldous AR， Dong JZ. Personalized neoantigen vaccines： a new approach to cancer immunotherapy［J］. Bioorg Med Chem， 2018， 26（10）： 2842-2849.
    [39]
    Chen FJ， Zou ZY， Du J， et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors［J］. J Clin Invest， 2019， 129（5）： 2056-2070.
    [40]
    Hilf N， Kuttruff-Coqui S， Frenzel K， et al. Actively personalized vaccination trial for newly diagnosed glioblastoma［J］. Nature， 2019， 565（7738）： 240-245.
    [41]
    Keskin DB， Anandappa AJ， Sun J， et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial［J］. Nature， 2019， 565（7738）： 234-239.
    [42]
    Zang R， Jiang T， Zeng TZ， et al. Advances of combined immunotherapy in tumor［J］. J China Pharm Univ （中国药科大学学报）， 2018， 49（4）： 383-391.
    [43]
    Sahin U， ?Türeci. Personalized vaccines for cancer immunotherapy［J］. Science， 2018， 359（6382）： 1355-1360.
    [44]
    Hennessy ML， Bommareddy PK， Boland G， et al. Oncolytic immunotherapy［J］. Surg Oncol Clin N Am， 2019， 28（3）： 419-430.
    [45]
    Bommareddy PK， Shettigar M， Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy［J］. Nat Rev Immunol， 2018， 18（8）： 498-513.
    [46]
    Breitbach CJ， Bell JC， Hwang TH， et al. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec （JX-594）［J］. Oncolytic Virother， 2015， 4： 25-31.
    [47]
    Kaufman HL， Kohlhapp FJ， Zloza A. Oncolytic viruses： a new class of immunotherapy drugs［J］. Nat Rev Drug Discov， 2015， 14（9）： 642-662.
    [48]
    Rosewell Shaw A， Suzuki M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment［J］. Front Immunol， 2018， 9： 2103.
    [49]
    Russell L， Peng KW， Russell SJ， et al. Oncolytic viruses： priming time for cancer immunotherapy［J］. BioDrugs， 2019， 33（5）： 485-501.
    [50]
    Tsun A， Miao XN， Wang CM， et al. Oncolytic immunotherapy for treatment of cancer［J］. Adv Exp Med Biol， 2016， 909： 241-283.
    [51]
    Yl?sm?ki E， Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy［J］. Curr Opin Biotechnol， 2020， 65： 25-36.
    [52]
    Qin S， Xu LP， Yi M， et al. Novel immune checkpoint targets： moving beyond PD-1 and CTLA-4［J］. Mol Cancer， 2019， 18（1）： 155.
    [53]
    Xin X， Pei X， Yang X， et al. Rod-shaped active drug particles enable efficient and safe gene delivery［J］. Adv Sci （Weinh）， 2017， 4（11）： 1700324.
    [54]
    Xin XF， Teng C， Du XQ， et al. Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route［J］. Theranostics， 2018， 8（13）： 3474-3489.
    [55]
    Xin XF， Du XQ， Xiao QQ， et al. Drug nanorod-mediated intracellular delivery of microRNA-101 for self-sensitization via autophagy inhibition［J］. Nano-Micro Lett， 2019， 11（1）： 1-16.
    [56]
    Ma LY， Dichwalkar T， Chang JYH， et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor［J］. Science， 2019， 365（6449）： 162-168.
    • Related Articles

  • Related Articles

    [1]LIU Yuanyuan, HE Chao. Preparation，optimization and antibacterial activity of luteolin nanostructured lipid carriers[J]. Journal of China Pharmaceutical University, 2020, 51(6): 681-687. DOI: 10.11665/j.issn.1000-5048.20200606
    [2]GAO Liuzhou, XIE Yusuo, HUANG Wenlong, HU Guoqiang. Synthesis, antibacterial and antitumor activities of 1-cycloproyl-6-fluoro-7-(hydrazone)-quinolin-4(1H)-one-carboxylic acids[J]. Journal of China Pharmaceutical University, 2014, 45(6): 662-664. DOI: 10.11665/j.issn.1000-5048.20140607
    [3]HU Guo-qiang, HOU Li-li, WANG Guo-qiang, DUAN Nan-nan, WEN Xiao-yi, CAO Tie-yao, HUANG Wen-long. Synthesis and antitumor and antibacterial activities of fluoroquinolone C-3 isosteres I.norfloxacin C-3 carbonylhydrazone derivatives[J]. Journal of China Pharmaceutical University, 2012, 43(4): 298-301.
    [4]CHEN Guo-hua, REN Zhong, YANG Yang, WU Fei-hua. Synthesis and antibacterial activity of novel fourth-generation cephalosporin compounds[J]. Journal of China Pharmaceutical University, 2009, 40(5): 395-399.
    [6]In vitro and In vivo Antibacterial Activities of Fleroxacin Injection[J]. Journal of China Pharmaceutical University, 1997, (5): 53-57.
    [7]Synthesis and Antimicrobial Activity of Triazolylcepha-losporins[J]. Journal of China Pharmaceutical University, 1993, (6): 321-326.
    [8]Preparation and Antibacterical Activity of Four New Complexes Between La, Pr, Nd or Sm and Lomefloxacin[J]. Journal of China Pharmaceutical University, 1993, (5): 308-310.
    [9]Synthesis and Antibacterial Activity of 6, 8-Difluoro Quinolones[J]. Journal of China Pharmaceutical University, 1993, (5): 264-268.
    [10]Antimicrobial Activity (in Vitro) of the Constituents of Bulbus Fritillariae[J]. Journal of China Pharmaceutical University, 1992, (3): 188-189.

  • Cited by

    Periodical cited type(8)

    1. 龚蕾蕾. 纳米药物递送系统治疗乳腺癌的研究进展. 医学理论与实践. 2023(06): 939-941 .
    2. 卓新雨，张艾立，马菲，崔志磊，刘臻，谢恬. 纳米载药系统的研究进展. 广东化工. 2022(10): 85-87 .
    3. 刘盼，王路，董能峰，刘力，李炳生. 量子点的制备及其在药物检测和药物递送领域中的应用. 广东化工. 2021(08): 152-153+151 .
    4. 文鹏，石峰. 纳米材料在肿瘤治疗中的研究进展. 肿瘤药学. 2021(02): 153-157+164 .
    5. 程晓昆，张越，吕海军，刘歆颖，侯森林，陈爱兵. 多孔碳纳米材料构建抗肿瘤药物靶向传递系统的研究进展. 无机材料学报. 2021(01): 9-24 .
    6. 王小宁，闫梦茹，马远涛，梁晓燕，罗国平. 载紫杉醇聚(2-乙基-2-噁唑啉)修饰单壁碳纳米管递药系统的制备及体外抗肿瘤作用评价. 中草药. 2020(03): 607-615 .
    7. 王鹏. 基于碳纳米线圈的细胞应激性测试探针. 云南大学学报(自然科学版). 2020(05): 941-948 .
    8. 李学暖，李天昊，张嘉琳，黎孔月，蒋靖超，程昊. 多壁碳纳米管修饰玻碳电极电致化学发光测奈福泮. 广西科技大学学报. 2020(04): 124-131 .

    Other cited types(8)

Catalog

    Get Citation
    PDF
    XML
    Article views (1773) PDF downloads (1652) Cited by(16)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：436775

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return